Literature DB >> 25149079

Oncological and functional outcomes of transoral surgery for the treatment of oropharyngeal cancer.

P Chauhan1, H Byrne1, E Taylor2, P Sheahan3.   

Abstract

BACKGROUND: Currently, most cases of oropharyngeal squamous cell carcinoma (OPSCC) are treated by chemoradiotherapy. However, serious concerns have arisen regarding toxicity and poor functional outcomes. Recently, transoral techniques for resection of selected OPSCC have been developed. AIMS: To review the outcomes of transoral surgery for OPSCC at our institution.
METHODS: Retrospective review of 12 patients with OPSCC treated with transoral resection. Data on surgical complications, oncological outcomes, and functional outcomes were analysed.
RESULTS: Primary sites were tonsil (9), soft palate (1), base of tongue (1), and posterior pharyngeal wall (1). There were no surgical complications. After the mean follow-up of 19 months, there were no local or regional recurrences. Two patients (one with synchronous lung cancer) died from distant metastases. No patient required gastrostomy tube or had long-term speech or swallowing impairments.
CONCLUSION: Transoral resection is an excellent option for selected patients with OPSCC, offering excellent functional and oncological outcomes.

Entities:  

Keywords:  Human papilloma virus; Oropharynx cancer; Radiotherapy; Surgery; Transoral

Mesh:

Year:  2014        PMID: 25149079     DOI: 10.1007/s11845-014-1183-3

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  28 in total

1.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

2.  Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

Authors:  T G Wendt; G G Grabenbauer; C M Rödel; H J Thiel; H Aydin; R Rohloff; T P Wustrow; H Iro; C Popella; A Schalhorn
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

4.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

5.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

6.  Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery.

Authors:  David G Grant; Michael L Hinni; John R Salassa; William C Perry; Richard E Hayden; John D Casler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-12

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

8.  Case-control study of human papillomavirus and oropharyngeal cancer.

Authors:  Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

9.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

10.  Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems.

Authors:  Fabrice Denis; Pascal Garaud; Etienne Bardet; Marc Alfonsi; Christian Sire; Thierry Germain; Philippe Bergerot; Béatrix Rhein; Jacques Tortochaux; Patrick Oudinot; Gilles Calais
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-01-01       Impact factor: 7.038

View more
  2 in total

1.  The impact of human papillomavirus (HPV) status on functional outcomes and quality of life (QOL) after surgical treatment of oropharyngeal carcinoma with free-flap reconstruction.

Authors:  Hani Z Marzouki; Vincent L Biron; Peter T Dziegielewski; Andrew Ma; Jason Vaz; Gabriela Constantinescu; Jeffrey Harris; Daniel O'Connell; Hadi Seikaly
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-09-19

2.  Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma.

Authors:  Clara Backes; Henning Bier; Andreas Knopf
Journal:  Oncotarget       Date:  2017-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.